Zylera Pharmaceuticals

Zylera Pharmaceuticals was a specialty pharmaceutical company focusing on the development, acquisition, and commercialization of prescription pharmaceutical products and dietary supplements, primarily in the pediatric space. Its commercial products, such as Poly-Vi-Flor and Tri-Vi-Flor, were vitamin and fluoride supplements for infants and children. There is no evidence of an active proprietary drug pipeline post-acquisition; previous drug candidates (e.g., ZYL-3177X, ZYL-65987) were discontinued. The company was acquired by Cerecor in 2017 and appears to have shifted focus from proprietary R&D to being a commercial revenue stream supporting the parent's pipeline development.